Richard Stone, MD | Authors


An Overview of the CALGB 10603 Trial in AML

August 05, 2016

Richard M. Stone, MD, Program Director, Adult Leukemia Program, Dana-Farber Cancer Institute, discusses the CALGB 10603 trial, which explored the use of midostaurin as a treatment for patients with FLT3-mutated acute myeloid leukemia.